👨‍⚕ Ángel Carracedo (Santiago de Compostela, Spain)

Chairpersons:
👨‍⚕ Rafael Bañares (Madrid, Spain)
👨‍⚕Francisco Jorquera (León, Spain)

Is there a need for specialized units?
👨‍⚕ Manuel Romero (Sevilla, Spain)

The role of the geneticist
👩‍⚕️ Nerea Paz (Santander, Spain)

Chairpersons:
👨‍⚕ Conrado Fernández (Madrid, Spain)
👨‍⚕ José Presa (Vila Real, Portugal)

Natural history in PBC
👨‍⚕ Christophe Corpechot (Paris, France)

Personalized treatment in PBC
👨‍⚕ Gideon M. Hirschfield (Toronto, Canada)

Chairpersons:
👩‍⚕ María Buti (Barcelona, Spain)
👨‍⚕ Rafael Esteban (Barcelona, Spain)

Do we know the natural history of delta hepatitis?
👨‍⚕ José Luis Calleja (Madrid, Spain)

Therapeutic options in hepatitis delta
👨‍⚕ Marc Bourlière (Marseille, France)

Real Life experience in Hepatitis delta treatment
👨‍⚕ Pietro Lampertico (Milan, Italy)

Porto-sinusoidal vascular disease (PSVD)
👩‍⚕ Virginia Hernández-Gea (Barcelona, Spain)

Fontan associated liver disease
👨‍⚕ Luis Téllez (Madrid, Spain)

Coffee Break & Visit Art Exhibition

Chairpersons:
👩‍⚕ Marina Berenguer (Valencia, Spain)
👩‍⚕ Elba Llop (Madrid, Spain)

What is the best treatment for Wilson’s disease today?
👨‍⚕ Michael L. Schilsky (New Haven, United States)

Do real-life registries improve care?
👩‍⚕ Zoe Mariño (Barcelona, Spain)

Chairpersons:
👨‍⚕ Jose Luis Calleja (Madrid, Spain)
👨‍⚕ JavierCrespo (Santander,Spain)

👨‍⚕ Julio Mayol (Madrid, Spain) v.s Clinical experts and audience

Chairpersons:
👨‍⚕ Jesús Bañales (San Sebastián, Spain)
👨‍⚕Raúl Andrade (Málaga, Spain)

Genetics of alpha 1 AT deficiency
👨‍⚕ Pavel Strnad (Aachen, Germany)

Progressive familial intrahepadc cholestasis
👨‍⚕ Richard J. Thompson (London, England)

New therapeutic options in Polycistic Liver disease
👨‍⚕ Joost Drenth (Nijmegen, Netherlands)

Hereditary hemochromatosis pathogenesis
👩‍⚕ Elena Corradini (Modena, Italy)

Chairpersons:
👩‍⚕ Ángela Puente (Santander, Spain)
👨‍⚕ Agustín Albillos (Madrid, Spain)

Integrate genomic data into clinical practice
👨‍⚕ Luca Valenti (Milan, Italy)

How to discover a disease: From the patient’s bedside to the laboratory
          The clinician’s question
          👨‍⚕ Álvaro Díaz (Santander, Spain)
          The basic’s answer
          👨‍⚕ José Juan García Marín (Salamanca, Spain)

MASLD genetic risk variants and personalized treatment
👨‍⚕ Stefano Romeo (Catanzaro, Italy)

New approaches for the treatment of liver diseases
👩‍⚕ Mariluz Martínez-Chantar (Derio, Spain)

Chairpersons:
👩‍⚕ María Teresa Arias Loste (Santander, Spain)
👨‍⚕ Marcos López Hoyos (Santander, Spain)

One million genomes project
👨‍⚕ André G. Uitterlinden (Rotterdam, Netherlands)

Cohorte Cantabria
👨‍⚕ Marcos López Hoyos (Santander, Spain)

👨‍⚕ José Luis Calleja (Madrid, Spain)

👨‍⚕ Javier Crespo (Santander, Spain)